Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1150 mg double-blinded secukinumab
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
2150 mg open-label secukinumab
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
3300 mg double-blinded secukinumab
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
4Cosentyx1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬4件: 41, 107, 269, 271 💬
5COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 107 💬
6COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 107 💬
7Cosentyx 300 mg solution for injection in pre-filled syringe1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
8Cosentyx 300mg solution for injection in pre-filled syringe1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
9Cosentyx®1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 269 💬
10SECUKINUMAB
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
11Secukinumab (150 mg)
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
12Secukinumab (75 mg)
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
13Secukinumab (AIN457)
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 46 💬
14Secukinumab (AIN457) 150 mg s.c.
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
15Secukinumab 150 mg
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
16Secukinumab 150 mg (2 injections per dose
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 269 💬
17Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
18Secukinumab 150 mg/1 ml Solution for injection
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬2件: 37, 271 💬
19Secukinumab 150 mg/ml
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
20Secukinumab 150 milligram [Cosentyx]1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
21Secukinumab 150mg
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
22Secukinumab 300 mg
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
23Secukinumab 300 mg, s.c.
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 41 💬
24Secukinumab 300mg
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 37 💬
25Secukinumab 75 mg/0.5 ml Solution for injection
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 271 💬
26Secukinumab Injection
(Cosentyx (TN))		1件: Secukinumab (Cosentyx)1件: Secukinumab (Cosentyx (TN)) 💬 1件: IL17A 💬 6件: Alcoholic liver disease, Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Inflammatory bowel disease, Rheumatoid arthritis, Th17 cell differentiation 💬1件: 160 💬